To compare the effects of the care bundles including chlorhexidine dressing and advanced dressings on the catheter-related bloodstream infection (CRBSI) rates in pediatric hematology-oncology patients with central venous catheters (CVCs).
Abstract:
PURPOSE: To compare the effects of the care bundles including chlorhexidine dressing and advanced dressings on the catheter-related bloodstream infection (CRBSI) rates in pediatric hematology-oncology patients with central venous catheters (CVCs).
METHOD: Twenty-seven PHO patients were recruited to participate in a prospective, randomized study in Turkey. The researcher used care bundles with chlorhexidine dressing in the experimental group (n = 14), and care bundles with advanced dressings in the control group (n = 13).
RESULTS: According to the study results, 28.6% of the patients in the experimental group had CRBSI, while this rate was 38.5% in the control group patients. The CRBSI rate in the experimental group was 3.9, and the control group had 4.4 per 1000 inpatient catheter days. There was no exit-site infection in the experimental group. However, the control group had 1.7 per 1000 inpatient catheter days.
[ctt link=”elcc7″ template=”1″]ReTweet if useful… Randomized controlled trial of care bundles with chlorhexidine and advanced IV dressings https://ctt.ec/elcc7+ @ivteam #ivteam[/ctt]
CONCLUSIONS: Even though there was no difference between the two groups in which the researcher implemented care bundles with chlorhexidine dressing and advanced dressings in terms of CRBSI development, there was reduction in the CRBSI rates thanks to the care bundle approach. It is possible to control the CRBSI rates using care bundles in pediatric hematology-oncology patients.
Reference:
Gerçeker, G.Ö., Yardımcı, F. and Aydınok, Y. (2017) Randomized controlled trial of care bundles with chlorhexidine dressing and advanced dressings to prevent catheter-related bloodstream infections in pediatric hematology-oncology patients. European Journal of Oncology Nursing. June 28th. Epub 2017 March 4th.
doi: 10.1016/j.ejon.2017.02.008.
Thank you to our partners for supporting IVTEAM
[slideshow_deploy id=’23788’]